Published in final edited form as:

Cytokine. 2017 December ; 100: 11–15. doi:10.1016/j.cyto.2017.08.015.

Origin and production of inflammatory perivascular macrophages in pulmonary hypertension

Jonathan Florentin¹ and Partha Dutta^{1,2}

¹Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

²Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Abstract

Myeloid cells, including monocytes and macrophages participate in steady state immune homeostasis and help mount the adaptive immune response during infection. The function and production of these cells in sterile inflammation, such as pulmonary hypertension (PH), is understudied. Emerging data indicate that pulmonary inflammation mediated by lung perivascular macrophages is a key pathogenic driver of pulmonary remodeling leading to increased right ventricular systolic pressure (RVSP). However, the origin of these macrophages in pulmonary inflammation is unknown. Inflammatory monocytes, the precursors of pathogenic macrophages, are derived from hematopoietic stem and progenitor cells (HSPC) in the bone marrow and spleen during acute and chronic inflammation. Understanding the role of these organs in monocytopoiesis, and the mechanisms of HSPC proliferation and differentiation in PH are important to discover therapeutic targets curbing inflammation. This review will summarize the current limited knowledge of the origin of lung macrophage subsets and over-production of inflammatory monocytes in PH.

Keywords

alveolar macrophages; interstitial macrophages; inflammation; pulmonary hypertension; HSC progenitors

Introduction

PH is a progressive cardiopulmonary disease leading to right ventricular failure, multi-organ dysfunction and often death. The vascular manifestations of PH are associated with cellular

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author contributions:

JF and PD were involved in writing the manuscript.

Conflict of interest:

The authors declare that they have no competing interests.

and soluble inflammatory mediators [1–3]. There is growing appreciation that pulmonary vascular inflammation, involving multiple immune cells, plays a key role in the development and progression of vascular remodeling in PH [4–6]. This review will focus on the relevance of myeloid cells, especially monocytes and macrophages in PH and will shed light on the recent related discoveries.

Monocytes constitute an important part of the innate immune system. They are generated by hematopoietic progenitor cells, which are located in hematopoietic organs such as bone marrow and spleen. In mice, monocytes fall into two main subsets: proinflammatory Ly-6c^{high} Cx3cr1^{low} [7] and patrolling Ly-6c^{low} Cx3cr1^{high} [8]. Humans have three distinct monocyte subsets: CD14^{high} CD16^{low} (inflammatory, classical), CD14^{high} CD16^{int} (intermediate), and CD14^{int} CD16^{high} (patrolling, non-classical) [9]. Monocytes can trigger inflammation in various diseases. Human classical and intermediate monocytes are thought to be inflammatory [10–12]. However, in some inflammatory diseases, human non-classical monocytes have been shown to have pro-inflammatory features [13–15]. Chemokines, such as CX3CL1 and CCL2, help monocytes egress from the bone marrow and migrate to tissues where they help orchestrate adaptive immune responses through their role of antigen presentation. Once in injured tissues, they may differentiate into macrophages and dendritic cells. However, this notion has been challenged by a recent study [16] reporting that there is a minimum differentiation of monocytes as they survey tissues and carry antigens to lymph nodes. Macrophages are phagocytic cells that participate in the clearance of tissue debris and foreign materials, and tissue homeostasis. Recent evidences showed the importance of macrophages in aggravating inflammation in PH.

Origin of monocytes and macrophages

Monocytes in adult mammals are produced from hematopoietic stem cells (HSC) in hematopoietic organs such as bone marrow (BM) and spleen. However, most tissue resident macrophages are not derived from HSC in the steady state. Ontogenically, macrophages can be divided in two classes: embryo- and monocyte-derived macrophages. Tissue resident macrophages, such as microglia, Kupffer cells, peritoneal, and splenic and lung macrophages, arise from two successive steps of hematopoiesis: primitive and definitive hematopoiesis during fetal period [17–19]. During primitive hematopoiesis, which occurs in early embryonic stage, erythroid myeloid progenitors from the yolk sac seed different organs and can differentiate into macrophages without intermediate monocyte stage [16, 20]. These cells self-maintain by proliferation and perform homeostatic functions in tissues at steady state [21]. During later embryonic stage, macrophages can be produced by fetal liver monocytes. Seeding of fetal liver monocytes in different tissues depends on plasmalemmal vesicle-associated protein [22]. Macrophages can also be derived from bone marrow-derived monocytes at steady state. Monocytes are continuously recruited into organs, such as the intestine [23], that have high macrophage turnover. Once in tissues, monocytes differentiate into macrophages [24]. It is likely that the origin of macrophages depends on the availability of niches [23]. For example, yolk sac-derived erythroid myeloid progenitors seed the brain during embryonic day 8 when the blood brain barrier is not established and differentiate into microglia. Moreover, during inflammatory processes that compromise the blood brain barrier, the local demand of myeloid cells especially macrophages is high and tissue resident

macrophages disappear due to their increased apoptosis, resulting in empty macrophage niches. To fill the empty niches, monocytes rapidly egress from bone marrow and are recruited to inflamed tissues where they can differentiate into macrophages. Various reports showed that human classical monocytes or their murine counterpart Ly-6C^{high} monocytes are the source of macrophages in pathological context such as cancer [25, 26], atherosclerosis [27] and metabolic diseases [28]. Embryonic macrophages can be slowly replaced by circulating monocytes at steady state [29]. Recent studies indicate that, irrespective of the origin of macrophages, their phenotype and function depend on the local environment where they reside [30, 31].

Function and origin of lung macrophages

The lungs consist of mainly two kinds of macrophages: interstitial macrophages and alveolar macrophages. Alveolar macrophages are found in alveoli lumen. They participate in local immune homeostasis and have certain surfactant properties [32, 33]. Additionally, alveolar macrophages are important cellular assets to protect the lungs from viral infections such as Influenza [34]. Interstitial macrophages reside in lung interstitium where they interact with interstitial T lymphocytes and trigger an adaptive immune response [35–37] and are considered as antigen presenting cells in the lungs [38].

Initial histological and immunohistochemical studies showed that embryonic lung macrophages derived from the yolk sac sequentially differentiate into interstitial macrophages and then alveolar macrophages after birth [39–43]. Alveolar macrophages are renewed by patrolling monocytes with interstitial macrophages as intermediates. However, this theory of alveolar macrophage development has been challenged by recent studies using cell fate mapping and parabiosis experiments. These studies provide evidence that alveolar macrophages can divide and self-renew without being replaced by circulating monocytes in the steady state [44–47]. Further adoptive transfer and lineage tracing experiments show that alveolar macrophages are derived from fetal liver monocytes, not yolk sac [48]. [2]. PPAR- γ expression, on fetal liver monocytes, driven by GM-CSF in embryonic lungs is important for the development of alveolar macrophages [49].

It has been shown that interstitial macrophages are derived from blood monocytes at steady state [50]. However, the origin of the lung macrophage subsets in inflammatory conditions is not well understood. Recently, Misharin et al. observed a novel population of alveolar macrophages, which are derived from blood monocytes in the context of pulmonary fibrosis [51]. This population of monocyte-derived alveolar macrophages coexists with embryonic alveolar macrophages and express high levels of pro-fibrotic genes. Monocyte-derived alveolar macrophages persist in the lungs long after the resolution of fibrosis and gradually become similar to lung-resident macrophage subset. Besides fibrosis, interstitial and alveolar macrophages play a major role in lung inflammation [52] and function [52–56]. Moreover, their interplay is relevant in the context of PH. In line with this, Kurt Stenmark's group recently showed that, in a hypoxic mouse model of PH, activation and expansion of lung alveolar and interstitial macrophages was time and space dependent [57].

Importance of bone marrow-derived cells in PH pathogenesis

Plexiform lesions of the vasculature of PH patients contain markers of inflammation [58, 59]. Monocytes and macrophages are the main effector cells contributing to local lung inflammation in the context of PH [60–62]. Recruitment of immune cells to the lungs contributes to vascular destruction and remodeling in the pathogenesis of chronic lung diseases, such as PH [63, 64]. In response to stimuli, endothelial cells overproduce chemokines such as fractalkine (CX₃CL1) [65–70]. This triggers the attachment of leukocytes expressing CX₃CR1, the CX₃CL1 receptor, to lung endothelial cells [70–74]. The importance of monocyte infiltration into the lungs in PH is relatively understudied. Recently, Amsellem et al. showed that Cx₃cr1 plays a major role in hypoxia-induced PH by modulating monocyte recruitment, macrophage polarization, and smooth muscle cell proliferation in the lungs [75]. Congruently, *cx₃cr1*-deficient mice had an attenuated PH pathogenesis. Consistent with the importance of bone marrow-derived leukocytes in PH pathogenesis, a recent study has shown that TGF- β activation in the lungs by hematopoietic cell-derived thrombospondin-1 triggers *Schistosoma mansoni*-induced PH [76]. Prior work has suggested that expansion of lung macrophages in PH is dependent on circulating progenitors originated in the bone marrow [2, 77, 78]. However, the contribution of hematopoietic stem cells (HSCs) in the origin of inflammatory perivascular lung macrophages in pulmonary hypertension is unknown.

Generation of inflammatory myeloid cells in the bone marrow

HSCs are the source of myeloid cells. At steady state, most HSCs are quiescent as only approximately 5% of them are in the cell cycle [79]. However, stress can induce HSC proliferation and differentiation into hematopoietic progenitor cells [80], which can further differentiate into mature hematopoietic cells. Multiple studies reported that circulating alarmins, such as IFNs, secreted during infection or injury drive quiescent HSCs into cell cycle [81–83]. However, how HSCs sense danger still remains unclear. This is an interesting question in the context of cardiovascular diseases since we previously showed that myocardial infarction leads to HSC activation and differentiation [84, 85]. HSCs express high levels of pattern recognition receptors (PRR), such as Toll-like receptors, which help them sense danger [86]. When HSCs are stimulated with ligands for Toll-like receptors, they enter the cell cycle and differentiate into committed progenitors such as granulocyte and monocyte progenitors (GMP) [87], which are precursors of myeloid cells. Any alteration in bone marrow microenvironment can also affect HSC quiescence. In the context of myocardial infarction, decreased levels of HSC retention factors, such as Cxcl12, Scf, Ang-1 and Vcam-1, result in increased HSC proliferation and release from their niches. These retention factors are secreted by bone marrow niche cells, such as macrophages [88, 89], regulatory T cells [90], endothelial cells [91, 92] and CXCL12-abundant reticular cells [93], which are located in hematopoietic tissue in close proximity to HSCs and hematopoietic progenitors. Retention factors secreted by these niche cells maintain the hematopoietic niche, and regulate HSC proliferation and differentiation (Figure 1). Subtle modifications in HSC niche in disease conditions alter hematopoiesis. For example, in the context of atherosclerosis, high levels of G-CSF suppress CXCL12 production by osteoblasts, leading to HSC proliferation and release [94, 95]. As discussed above, multiple studies reported

blood and lung monocytosis in the context of PH [62, 75, 76]. The blood monocyte expansion depends on their generation in the bone marrow from hematopoietic stem and progenitor cells. Indeed, immunodeficient mice xenografted with human bone marrow progenitors obtained from patients with pulmonary arterial hypertension (PAH) exhibited PAH pathogenesis [96]. The molecular underpinnings of HSC activation in PH have not been studied well. The activation of the progenitor cells in the context of PH can be triggered by soluble factors such as hypoxia-inducible factor-1 (HIF-1) (Figure 1). Although there is no direct evidence of causative link between high levels of HIF-1 α and HSC activation in PH, Fahra et al., showed that patients with PAH had high levels of HIF-1 α -activating factors erythropoietin, stem cell factor and hepatocyte growth factor, which are involved in HSC activation [97]. HIF-1 α is a transcription factor that helps mount adaptive responses to hypoxia [98] and induces transcription of genes involved in angiogenesis, erythropoiesis, energy metabolism and cell survival [99]. Multiple studies highlighted the role of HIF-1 α in PH. For example, HIF-1 α deficiency in *Hif1a*^{+/-} hypoxic mice showed attenuated PH manifestations [100]. Additionally, smooth muscle-specific HIF-1 α -deficient mice displayed less pulmonary vascular remodeling [101]. In line with these findings, patients with severe PH displayed increased expression of HIF-1 α in proliferating pulmonary arterial endothelial cells [102]. Overall, these data suggest that HIF-1 α might be a suitable therapeutic target. Congruently, Wong et al. reported that the use of Simvastatin and different Rho kinase inhibitors, which allow the cleavage of HIF-1 α , reversed PH in newborn rats [103]. Moreover, micro RNA 150 alleviated hypoxia induced PH by inhibiting HIF-1 α expression [103]. Drugs targeting HIF-1 α expression have been used to decrease PH severity [104, 105].

Resolution of inflammation: toward new therapeutic approaches to decrease PH pathogenesis

There is an urgent need of developing novel anti-inflammatory therapies in PH since currently approved PH therapies do not cure, prevent, or regress this disease [106]. Notably, anti-inflammatory therapies may differ from the available pulmonary vasodilators, which primarily control vasomotor tone and dilate partially occluded pulmonary arteries [107, 108] rather than acting as anti-remodeling agents. Since macrophages are the major cell types contributing to local lung inflammation in PH, drugs targeting monocytes, which are macrophage precursors, and monocyte progenitors in the bone marrow will prevent the initiation of lung remodeling. Thus multiple therapeutic options to check inflammatory monocyte and macrophage-mediated tissue remodeling need to be explored: A) inhibition of bone marrow myelopoiesis: The CXC chemokine stromal derived factor-1 (SDF-1/CXCL12) and its receptor CXCR4 play a major role in regulating mobilization and differentiation of hematopoietic progenitor cells [109]. The use of CXCR4 inhibitor has shown to target C-kit⁺ progenitor cells and decrease PH features [110]. Recently, in line with this finding, Favre et al. showed that Sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor, decreased recruitment of C-kit⁺ cells leading to improved pulmonary hemodynamic [111]. B) Reduction of monocyte numbers in the lungs: Monocyte numbers in the lungs could be reduced in two different ways: a) inhibition of monocyte egress from the bone marrow and b) suppressing monocyte recruitment into the lungs. Chemokine receptors,

such as CX₃CR1 and CCR2, play crucial roles in monocyte egress and recruitment [75]. We successfully blocked monocyte egress from the bone marrow in mouse models of myocardial infarction and atherosclerosis using siRNA against CCR2 [112]. Additionally, depletion of the chemokines, such as CCL2 and CX3CL1, specifically in the lungs will prevent the infiltration of monocytes.

To summarize, we have just started understanding the role of inflammatory innate cells in PH pathogenesis. However, their production and mobilization to the lungs in PH is poorly understood. Since inflammation-mediated pulmonary tissue remodeling in PH is irreversible, there is an urgent need to understand the origin of lung-infiltrating myeloid cells to check inflammation and prevent remodeling of pulmonary blood vessels.

Acknowledgments

This work was supported by National Institute of Health grant 4R00HL121076-03. Figure 1 was adapted from the Servier Medical Art (www.servier.com).

References

1. Sawada H, et al. Reduced BMP2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. *J Exp Med*. 2014; 211(2): 263–80. [PubMed: 24446489]
2. Frid MG, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. *Am J Pathol*. 2006; 168(2):659–69. [PubMed: 16436679]
3. Hwangbo C, et al. Modulation of Endothelial BMP2 Activity by VEGFR3 in Pulmonary Arterial Hypertension. *Circulation*. 2017
4. Mathew R, et al. Hematological disorders and pulmonary hypertension. *World J Cardiol*. 2016; 8(12):703–718. [PubMed: 28070238]
5. Mouraret N, et al. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. *Circulation*. 2013; 127(16):1664–76. [PubMed: 23513067]
6. Vergadi E, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. *Circulation*. 2011; 123(18):1986–95. [PubMed: 21518986]
7. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity*. 2003; 19(1):71–82. [PubMed: 12871640]
8. Auffray C, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. *Science*. 2007; 317(5838):666–70. [PubMed: 17673663]
9. Ingersoll MA, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. *Blood*. 2010; 115(3):e10–9. [PubMed: 19965649]
10. Frankenberger M, et al. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. *Blood*. 1996; 87(1):373–7. [PubMed: 8547664]
11. Belge KU, et al. The proinflammatory CD14⁺CD16⁺DR⁺⁺ monocytes are a major source of TNF. *J Immunol*. 2002; 168(7):3536–42. [PubMed: 11907116]
12. Idzkowska E, et al. The Role of Different Monocyte Subsets in the Pathogenesis of Atherosclerosis and Acute Coronary Syndromes. *Scand J Immunol*. 2015; 82(3):163–73. [PubMed: 25997925]
13. Mukherjee R, et al. Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematosus. *Sci Rep*. 2015; 5:13886. [PubMed: 26358827]
14. Zimmermann HW, et al. Functional contribution of elevated circulating and hepatic non-classical CD14⁺CD16⁺ monocytes to inflammation and human liver fibrosis. *PLoS One*. 2010; 5(6):e11049. [PubMed: 20548789]

15. Ramirez R, et al. Microinflammation in hemodialysis is related to a preactivated subset of monocytes. *Hemodial Int*. 2006; 10(Suppl 1):S24–7.
16. Jakubzick C, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity*. 2013; 39(3):599–610. [PubMed: 24012416]
17. Davies LC, et al. Tissue-resident macrophages. *Nat Immunol*. 2013; 14(10):986–95. [PubMed: 24048120]
18. Ajami B, et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat Neurosci*. 2007; 10(12):1538–43. [PubMed: 18026097]
19. Yona S, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity*. 2013; 38(1):79–91. [PubMed: 23273845]
20. Perdiguero EG, et al. The Origin of Tissue-Resident Macrophages: When an Erythro-myeloid Progenitor Is an Erythro-myeloid Progenitor. *Immunity*. 2015; 43(6):1023–4. [PubMed: 26682973]
21. Murray PJ, Wynn Murray TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol*. 2011; 11(11):723–37. [PubMed: 21997792]
22. Rantakari P, et al. Fetal liver endothelium regulates the seeding of tissue-resident macrophages. *Nature*. 2016; 538(7625):392–396. [PubMed: 27732581]
23. Guillems M, Scott Guillems CL. Does niche competition determine the origin of tissue-resident macrophages? *Nat Rev Immunol*. 2017; 17(7):451–460. [PubMed: 28461703]
24. Bain CC, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat Immunol*. 2014; 15(10):929–937. [PubMed: 25151491]
25. Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature*. 2011; 475(7355):222–5. [PubMed: 21654748]
26. Cortez-Retamozo V, et al. Origins of tumor-associated macrophages and neutrophils. *Proc Natl Acad Sci U S A*. 2012; 109(7):2491–6. [PubMed: 22308361]
27. Ingersoll MA, et al. Monocyte trafficking in acute and chronic inflammation. *Trends Immunol*. 2011; 32(10):470–7. [PubMed: 21664185]
28. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. *Nat Rev Immunol*. 2011; 11(11):738–49. [PubMed: 21984069]
29. Molawi K, et al. Progressive replacement of embryo-derived cardiac macrophages with age. *J Exp Med*. 2014; 211(11):2151–8. [PubMed: 25245760]
30. Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell*. 2014; 159(6):1312–26. [PubMed: 25480296]
31. van de Laar L, et al. Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages. *Immunity*. 2016; 44(4):755–68. [PubMed: 26992565]
32. Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol*. 2002; 64:775–802. [PubMed: 11826288]
33. Dranoff G, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. *Science*. 1994; 264:713+. [PubMed: 8171324]
34. Schneider C, et al. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. *PLoS Pathog*. 2014; 10(4):e1004053. [PubMed: 24699679]
35. Franke-Ullmann G, et al. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. *J Immunol*. 1996; 157(7):3097–104. [PubMed: 8816420]
36. Prokhorova S, Lavnikova N, Laskin DL. Functional characterization of interstitial macrophages and subpopulations of alveolar macrophages from rat lung. *J Leukoc Biol*. 1994; 55(2):141–6. [PubMed: 8301209]
37. Fathi M, et al. Functional and morphological differences between human alveolar and interstitial macrophages. *Exp Mol Pathol*. 2001; 70(2):77–82. [PubMed: 11263950]

38. Gong JL, et al. Interstitial lung macrophages interact with dendritic cells to present antigenic peptides derived from particulate antigens to T cells. *Immunology*. 1994; 81(3):343–51. [PubMed: 8206508]
39. Hoeffel G, et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. *J Exp Med*. 2012; 209(6): 1167–81. [PubMed: 22565823]
40. Sorokin SP, Hoyt RF Jr, Grant MM. Development of macrophages in the lungs of fetal rabbits, rats, and hamsters. *Anat Rec*. 1984; 208(1):103–21. [PubMed: 6711832]
41. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. *J Exp Med*. 1968; 128(3):415–35. [PubMed: 5666958]
42. Higashi K, et al. Ontogenetic development, differentiation, and phenotypic expression of macrophages in fetal rat lungs. *J Leukoc Biol*. 1992; 51(5):444–54. [PubMed: 1602238]
43. Takahashi K, Yamamura F, Naito M. Differentiation, maturation, and proliferation of macrophages in the mouse yolk sac: a light-microscopic, enzyme-cytochemical, immunohistochemical, and ultrastructural study. *J Leukoc Biol*. 1989; 45(2):87–96. [PubMed: 2536795]
44. Golde DW, Byers LA, Finley TN. Proliferative capacity of human alveolar macrophage. *Nature*. 1974; 247(5440):373–5. [PubMed: 4817856]
45. Murphy J, et al. The prolonged life-span of alveolar macrophages. *Am J Respir Cell Mol Biol*. 2008; 38(4):380–5. [PubMed: 18192503]
46. Epelman S, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity*. 2014; 40(1):91–104. [PubMed: 24439267]
47. Hashimoto D, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity*. 2013; 38(4):792–804. [PubMed: 23601688]
48. Guillemins M, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med*. 2013; 210(10):1977–92. [PubMed: 24043763]
49. Schneider C, et al. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. *Nat Immunol*. 2014; 15(11):1026–37. [PubMed: 25263125]
50. Misharin AV, et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. *Am J Respir Cell Mol Biol*. 2013; 49(4):503–10. [PubMed: 23672262]
51. Misharin AV, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. *J Exp Med*. 2017
52. Franke-Ullmann G, et al. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. *The Journal of Immunology*. 1996; 157(7):3097–3104. [PubMed: 8816420]
53. Bedoret D, et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. *The Journal of Clinical Investigation*. 2009; 119(12):3723–3738. [PubMed: 19907079]
54. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. *J Leukoc Biol*. 2001; 70(2):163–70. [PubMed: 11493607]
55. Bryant AJ, et al. Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis. *Pulm Circ*. 2015; 5(4):681–90. [PubMed: 26697175]
56. Yan L, et al. Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2016; 193(8):898–909. [PubMed: 26651104]
57. Pugliese SC, et al. A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension. *J Immunol*. 2017; 198(12):4802–4812. [PubMed: 28500078]
58. Tudor RM, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol*. 1994; 144(2):275–85. [PubMed: 7508683]

59. Dorfmueller P, et al. Chemokine RANTES in severe pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2002; 165(4):534–9. [PubMed: 11850348]
60. Rabinovitch M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. *Circ Res.* 2014; 115(1):165–75. [PubMed: 24951765]
61. Pugliese SC, et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. *Am J Physiol Lung Cell Mol Physiol.* 2015; 308(3):L229–52. [PubMed: 25416383]
62. Chen T, et al. Alveolar Hypoxia-Induced Pulmonary Inflammation: From Local Initiation to Secondary Promotion by Activated Systemic Inflammation. *J Vasc Res.* 2016; 53(5–6):317–329. [PubMed: 27974708]
63. Frid MG, et al. Circulating mononuclear cells with a dual, macrophage-fibroblast phenotype contribute robustly to hypoxia-induced pulmonary adventitial remodeling. *Chest.* 2005; 128(6 Suppl):583s–584s.
64. Stenmark KR, et al. Hypoxia, leukocytes, and the pulmonary circulation. *J Appl Physiol* (1985). 2005; 98(2):715–21. [PubMed: 15649883]
65. Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. *J Leukoc Biol.* 2006; 80(5):1156–64. [PubMed: 17056766]
66. Imaizumi T, et al. Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. *Tohoku J Exp Med.* 2000; 192(2):127–39. [PubMed: 11211312]
67. Harrison JK, et al. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. *J Leukoc Biol.* 1999; 66(6):937–44. [PubMed: 10614775]
68. Manes TD, Pober JS. Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4+ T cells. *J Immunol.* 2008; 180(12):8386–92. [PubMed: 18523306]
69. Moatti D, Vele O, Nemerson Y. Induction of fractalkine by endothelial cells under shear stress. *Blood Coagul Fibrinolysis.* 2004; 15(2):197. [PubMed: 15091008]
70. Schulz C, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. *Circulation.* 2007; 116(7):764–73. [PubMed: 17679613]
71. Cambien B, et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. *Blood.* 2001; 97(7):2031–7. [PubMed: 11264168]
72. Fong AM, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. *J Exp Med.* 1998; 188(8):1413–9. [PubMed: 9782118]
73. Green SR, et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. *J Immunol.* 2006; 176(12):7412–20. [PubMed: 16751386]
74. Imai T, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. *Cell.* 1997; 91(4):521–30. [PubMed: 9390561]
75. Amsellem V, et al. Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension. *Am J Respir Cell Mol Biol.* 2017
76. Kumar R, et al. TGF-beta activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. *Nat Commun.* 2017; 8:15494. [PubMed: 28555642]
77. Tan SY, Krasnow MA. Developmental origin of lung macrophage diversity. *Development.* 2016; 143(8):1318–27. [PubMed: 26952982]
78. Nakashima T, et al. Lung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis. *Am J Respir Crit Care Med.* 2013; 188(8):976–84. [PubMed: 24010731]
79. Wilson A, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell.* 2008; 135(6):1118–29. [PubMed: 19062086]
80. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. *Nat Rev Immunol.* 2011; 11(10):685–92. [PubMed: 21904387]

81. Baldridge MT, et al. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. *Nature*. 2010; 465(7299):793–7. [PubMed: 20535209]
82. Essers MA, et al. IFN α activates dormant haematopoietic stem cells in vivo. *Nature*. 2009; 458(7240):904–8. [PubMed: 19212321]
83. Zhao JL, et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. *Cell Stem Cell*. 2014; 14(4):445–459. [PubMed: 24561084]
84. Dutta P, et al. Myocardial infarction accelerates atherosclerosis. *Nature*. 2012; 487(7407):325–9. [PubMed: 22763456]
85. Dutta P, et al. Myocardial Infarction Activates CCR2(+) Hematopoietic Stem and Progenitor Cells. *Cell Stem Cell*. 2015; 16(5):477–87. [PubMed: 25957903]
86. Nagai Y, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. *Immunity*. 2006; 24(6):801–12. [PubMed: 16782035]
87. Takizawa H, et al. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. *J Exp Med*. 2011; 208(2):273–84. [PubMed: 21300914]
88. Chow A, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. *J Exp Med*. 2011; 208(2):261–71. [PubMed: 21282381]
89. Winkler IG, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. *Blood*. 2010; 116(23):4815–28. [PubMed: 20713966]
90. Fujisaki J, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. *Nature*. 2011; 474(7350):216–9. [PubMed: 21654805]
91. Ding L, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature*. 2012; 481(7382):457–62. [PubMed: 22281595]
92. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. *Nature*. 2013; 495(7440):231–5. [PubMed: 23434755]
93. Sugiyama T, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity*. 2006; 25(6):977–88. [PubMed: 17174120]
94. Schuettelpelz LG, et al. G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling. *Leukemia*. 2014; 28(9):1851–60. [PubMed: 24518205]
95. Schuettelpelz LG, Link DC. Regulation of hematopoietic stem cell activity by inflammation. *Front Immunol*. 2013; 4:204. [PubMed: 23882270]
96. Asosingh K, et al. Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension. *Blood*. 2012; 120(6):1218–27. [PubMed: 22745307]
97. Farha S, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. *Blood*. 2011; 117(13):3485–93. [PubMed: 21258008]
98. Wang GL, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A*. 1995; 92(12):5510–4. [PubMed: 7539918]
99. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer*. 2003; 3(10):721–32. [PubMed: 13130303]
100. Yu AY, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 α . *J Clin Invest*. 1999; 103(5):691–6. [PubMed: 10074486]
101. Ball MK, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1 α . *Am J Respir Crit Care Med*. 2014; 189(3):314–24. [PubMed: 24251580]
102. Tuder RM, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. *J Pathol*. 2001; 195(3):367–74. [PubMed: 11673836]
103. Wong MJ, et al. Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling. *Am J Physiol Lung Cell Mol Physiol*. 2016; 311(5):L985–L999. [PubMed: 27694473]

104. Xu D, et al. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. *Int J Med Sci.* 2016; 13(12):942–954. [PubMed: 27994500]
105. Wang YX, et al. Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1–7) in rats. *Eur Rev Med Pharmacol Sci.* 2016; 20(15):3304–12. [PubMed: 27467008]
106. Tian W, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. *Sci Transl Med.* 2013; 5(200):200ra117.
107. Perrin S, et al. New pharmacotherapy options for pulmonary arterial hypertension. *Expert Opin Pharmacother.* 2015; 16(14):2113–31. [PubMed: 26290279]
108. Taichman DB, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest.* 2014; 146(2):449–75. [PubMed: 24937180]
109. Jin DK, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. *Nat Med.* 2006; 12(5):557–67. [PubMed: 16648859]
110. Gambaryan N, et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. *Eur Respir J.* 2011; 37(6):1392–9. [PubMed: 20884740]
111. Favre S, et al. Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells. *J Cell Mol Med.* 2017; 21(5):871–880. [PubMed: 27860185]
112. Leuschner F, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. *Nat Biotechnol.* 2011; 29(11):1005–10. [PubMed: 21983520]

Figure 1. Bone marrow myelopoiesis in pulmonary hypertension

HIF-1 α produced by endothelial cells and fibroblasts in pulmonary hypertension (PH) decreases production of hematopoietic stem cell (HSC) retention factors by hematopoietic niche cells. HSC proliferates and differentiates into committed progenitors such as granulocyte and macrophage progenitors (GMP). Newly generated monocytes egress from the bone marrow and infiltrate into inflamed lungs. Once in the lung interstitium, monocytes differentiate into interstitial macrophages (IM). Intermediate IMs may differentiate into monocyte-derived alveolar macrophages (AM). Resident alveolar macrophages (rAM) are not monocyte-derived and have ability to self-renew. These interstitial macrophages and monocyte-derived alveolar macrophages secrete cytokines that encourage inflammation and fibrosis, leading to lung remodeling.